Novus Cannabis MedPlan Reports Strong Q3 2025 Results with 18.1% EBITDA Growth

Novus Acquisition and Development Corp., operating as Novus Cannabis MedPlan, reported third-quarter 2025 financial results showing substantial growth in profitability and revenue. The company, which trades on the OTC Markets under the symbol NDEV, operates as an ancillary "non-plant-touching" business that provides proprietary prescription drug programs and traditional medical plans with cannabis benefits without directly growing, processing, or selling cannabis.

For the nine months ended September 30, 2025, Novus demonstrated strong operational leverage with EBITDA growing 18.1% to $152,572, significantly outpacing revenue growth of 8.85%. Gross revenue increased to $300,044 from $273,462 during the same period last year. The company's cash and equivalents position strengthened to $235,782, representing a 7.2% year-over-year increase achieved through organic cash flow.

The financial performance reflects Novus's strategic allocation of resources to self-fund key market initiatives and expand its Provider and Health Plan Network. The company maintains a non-dilutive capital strategy, with the number of issued and outstanding shares remaining unchanged throughout the reporting period. No insiders have sold shares in the past three years, demonstrating management alignment with long-term shareholder performance.

Novus has developed a unique two-platform architecture that separates regulated healthcare operations from cannabis commerce. Platform A serves as the company's online pharmacy and benefits platform, handling 24,300 prescriptions for individuals with or without insurance, claims processing, and connections with healthcare providers. Platform B operates as a dedicated commerce platform for cannabis ordering that connects to the company's network of cannabis retailers while maintaining independence from government healthcare funding systems.

This operational structure provides significant market advantages, including access to the $100+ billion Health Savings Accounts and Flexible Spending Accounts market through legally secure processing methods. The functional separation creates regulatory barriers that allow Novus to mediate cannabis benefits while protecting the core business from federal and state policy fluctuations. The company's approach to treating cannabis as a separate risk category enables it to offer cannabis as a complementary benefit alongside traditional coverage.

Novus maintains a simplified capital structure with no outstanding or issued convertible notes, eliminating dilution risk from debt conversion. The company has implemented a Vendor Share Leak-Out Provision that contractually caps vendor stock sales at 15% of the preceding 30-day average daily trading volume to prevent undue selling pressure. The only debt obligation is a $168,789 loan from CEO Frank Labrozzi, which includes no equity conversion provisions.

Investors can access detailed financial information through the company's filings available at https://www.otcmarkets.com/stock/NDEV/disclosure. The company's investor relations materials are available at https://www.getnovusnow.com/investors, and current stock quotes can be found at https://www.otcmarkets.com/stock/NDEV/quote.

The company's financial results are particularly significant as they demonstrate the viability of cannabis-inclusive healthcare benefits within current regulatory frameworks. Novus's ability to achieve profitability growth while maintaining compliance positions the company as a potential leader in the emerging intersection of healthcare benefits and cannabis accessibility. The results suggest growing market acceptance of cannabis benefits within traditional healthcare structures, potentially paving the way for broader industry adoption.